Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by CalifDreamingon Jan 10, 2011 3:06pm
828 Views
Post# 17949781

RE: There will be new shares issued

RE: There will be new shares issuedLooking at their presentation, their capex program is closer to $55MM this year (add in more for G&A etc).  And while test rates indicate 3,900 bpd gross, they say they'll produce closer to 500 bpd.
They need to raise ~$35MM or more imo.  That's why the sp is getting creamed.  Looking at the current share price and aggressive selling by institutions,
.125 may be the price, adding 280MM more shares plus any warrants that may be issued.  QEI could end up with 1B shares fd if they aren't careful, effectively wiping out much of the upside absent more exploration success.
QEI management have failed miserably wrt to managing the sp and funding.  Most Colombian juniors have had strong buying interest and have backers willing to push the sp before the next round of funding.  QEI is seeing just the opposite...
Bullboard Posts